Abstract
To examine the long-term efficacy and safety of amlodipine in hypertensive children, data on prolonged use (≥6 months) of amlodipine in 33 children were reviewed. All children received amlodipine as sole therapy for their hypertension. Causes of hypertension included solid organ transplant (n=19), renal disease (n=7) primary hypertension (n=6), and drug-induced hypertension (n=1). Mean patient age at the start of amlodipine treatment was 9.8±4.8 years (range 1.3–16.9); there were 19 boys and 14 girls. Mean duration of amlodipine treatment was 20.4±11.5 months (range 6–48). Analysis of blood pressure and dosing data revealed that blood pressure reduction was sustained throughout the period of amlodipine treatment, while amlodipine dose remained stable (mean effective daily dose 0.17±0.12 mg/kg). No patient required discontinuation of amlodipine because of adverse effects.
This small study suggests that prolonged amlodipine treatment is well tolerated in hypertensive children and provides sustained blood pressure control. Further studies are necessary to determine what effects if any long-term calcium channel blocker treatment has on the growth and development of children with hypertension.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Murdoch D, Heel RC (1991) Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 41:478–505
Flynn JT, Pasko DA (2000) Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension. Pediatr Nephrol 15:302–316
Khattak S, Rogan JW, Saunder EF, Theis JG, Arbus GS, Koren G (1998) Efficacy of amlodipine in pediatric bone marrow transplant patients. Clin Pediatr (Phila)37:31–35
Pfammatter, JF, Clericetti-Affolter C, Trittmann AC, Busch K, Laux-End R, Bianchetti MG (1998) Amlodipine once-daily in systemic hypertension. Eur J Pediatr 157:618–621
Tallian KB, Nahata MC, Turman MA, Mahan JD, Hayes JR, Mentser MI (1999) Efficacy of amlodipine in pediatric patients with hypertension. Pediatr Nephrol 13:304–310
Rogan JW, Lyszkiewicz DA, Blowey D, Khattak S, Arbus GS, Koren G (2000) A randomized prospective crossover trial of amlodipine in pediatric hypertension. Pediatr Nephrol 14:1083–1087
Flynn JT, Smoyer WE, Bunchman TE (2000) Treatment of hypertensive children with amlodipine. Am J Hypertens 13:1061–1066
Vigier RO von, Franscini LMD, Bianda NDF, Pfister R, Casaulta-Aebischer C, Bianchetti MG (2001) Antihypertensive efficacy of amlodipine in children with chronic kidney diseases. J Hum Hypertens 15:387–391
Parker ML, Robinson RF, Nahata MC (2002) Amlodipine therapy in pediatric patients with hypertension. J Am Pharm Assoc 42:114–117
Gartenmann AC, Fossali E, von Vigier RO, Simonetti GD, Schmidtko J, Edefonti A, Bianchetti MG (2003) Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood. Kidney Int 64:1450–1454
Flynn JT, Warnick SJ (2002) Isradipine treatment of hypertension in children: a single-center experience. Pediatr Nephrol 17:748–753
National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents (1996) Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: A working group report from the National High Blood Pressure Education Program. Pediatrics 98:649–658
Nahata MC, Morosco RS, Hipple TF (1999) Stability of amlodipine besylate in two liquid dosage forms. J Am Pharm Assoc 39:375–377
Shirkey H (1968) Therapeutic orphans. J Pediatr 72:119–120
Schreiner MS (1998) Safety and effectiveness data: will children gain access? Am Heart J 136:4–5
Flynn JT. Pediatric use of antihypertensive medications: much more to learn (2001) Curr Ther Res Clin Exp 62:314–328
Blowey D (2002) Safety of the newer antihypertensive agents in children. Expert Opin Drug Saf 1:39–43
Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE (2003) Drug therapy: developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med 349:1157–1167
Wells TG (1999) Trials of antihypertensive therapies in children. Blood Press Monit 4:189–192
Flynn JT (2003) Successes and shortcomings of the FDA Modernization Act. Am J Hypertens 16:889–891
Trachtman H, Frank R, Mahan JD, Portman R, Restaino I, Matoo TK, Tou C, Klibaner M (2003) Clinical trial of extended-release felodipine in pediatric essential hypertension. Pediatr Nephrol 18:548–553
Flynn JT, Newburger JW, Daniels SR, Sanders SP, Portman RJ, Hogg RJ (2004) A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr 145:353–359
Flynn, JT, Mottes TA, Brophy PB, Kershaw DB, Smoyer WE, Bunchman TE (2001) Intravenous nicardipine for treatment of severe hypertension in children. J Pediatr 139:38–43
Flynn JT, Ludden T, Mahan Jr JD, Nahata MC, Robinson R, Arbus GS, Portman RJ, Greenleaf PA, Cropp AB (2002) Population pharmacokinetics of amlodipine in children with hypertension (abstract). Am J Hypertens 15 (4, Part 2): 206A
Andrawis NS, Abernathy DR (1992) Verapamil blocks basal and angiotensin II-induced RNA synthesis of rat aortic vascular smooth muscle. Biochem Biophys Res Commun 183:767–773
Acknowledgements
We thank Andrea Hackert and Divya Jain for data collection and Dr. Adrian Spitzer for his thoughtful review of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Flynn, J.T. Efficacy and safety of prolonged amlodipine treatment in hypertensive children. Pediatr Nephrol 20, 631–635 (2005). https://doi.org/10.1007/s00467-004-1781-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-004-1781-9